Current job opportunities are posted here as they become available.
Department: | Medical Affairs |
Location: |
About Summit:
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational
bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.
Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:
HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).
HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.
Overview of Role:
Summit Therapeutics is seeking an experienced and dynamic Medical Affairs Director to lead the development and implementation of medical strategies for ivonescimab targeting different solid tumor cancers. This role will involve close collaboration with cross-functional teams, including clinical development, regulatory affairs, and commercial operations, to support the investigation and eventual commercialization of ivonescimab in different indications. The ideal candidate is able to demonstrate effective planning and execution of medical affairs strategies leading to a successful development or adoption of an oncology therapy, as well as ability to analyze, summarize, and deliver complex scientific data to a multitude of audiences.
Overview of Role:
The Medical Science Liaison (MSL) is a field-based scientific expert specializing in Immuno-Oncology and related treatment options. They play a strategic role in supporting Summit’s scientific and business objectives throughout the oncology product lifecycle. MSLs act as the primary scientific communicators for Summit within their designated regions, engaging with healthcare professionals and supporting clinical site activities.
Combining strong business acumen, clinical expertise, and market awareness, MSLs serve as vital conduits of information to various stakeholders within Summit. Depending on therapeutic needs and product life cycles, their responsibilities may include clinical development and pipeline support.
Role and Responsibilities:
Experience, Education and Specialized Knowledge and Skills: